Hantz Financial Services Inc. Acquires 6,533 Shares of IQVIA Holdings Inc. $IQV

Hantz Financial Services Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 812.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 7,337 shares of the medical research company’s stock after purchasing an additional 6,533 shares during the period. Hantz Financial Services Inc.’s holdings in IQVIA were worth $1,973,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Compass Financial Management LLC bought a new position in shares of IQVIA during the 2nd quarter valued at about $27,000. Elevation Wealth Partners LLC boosted its stake in shares of IQVIA by 218.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after acquiring an additional 105 shares in the last quarter. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of IQVIA in the third quarter valued at about $30,000. Caitlin John LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $31,000. Finally, BOK Financial Private Wealth Inc. acquired a new position in IQVIA in the second quarter worth about $34,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Morgan Stanley upped their price objective on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, September 17th. Robert W. Baird upped their target price on IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 27th. Truist Financial upped their price objective on shares of IQVIA from $329.00 to $346.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, TD Cowen increased their target price on shares of IQVIA from $288.00 to $307.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.

Read Our Latest Stock Report on IQV

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the transaction, the insider owned 24,989 shares of the company’s stock, valued at $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The SEC filing for this sale provides additional information. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Performance

NYSE:IQV opened at $257.97 on Thursday. The business has a 50 day moving average price of $267.49 and a 200-day moving average price of $212.26. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $284.50. The firm has a market cap of $42.51 billion, a PE ratio of 31.35, a price-to-earnings-growth ratio of 2.29 and a beta of 1.16. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter last year, the company earned $3.00 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Read More

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.